The last 1/4ly did state “research and development expenditures in the December quarter relate to three clinical trials which have completed expensive clinical stage. Hence, future expenditures will be lower.” We don’t know however the payment terms for CRO and what % was still to be completed end December. However R&D expense in December 1/4ly was historically very high.
BIT Price at posting:
6.9¢ Sentiment: Buy Disclosure: Held
